Vivo Capital’s LB Pharmaceuticals LBRX Stock Holding History

Vivo Capital’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.7M	Hold	800,000	–	–	1.64%	21
2025 Q4	$17.8M	Hold	800,000	–	–	1.15%	23
2025 Q3	$12.6M	Buy	+800,000	New	+$12.7M	1.02%	27

Other funds holding LBRX

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Spruce Street Capital New York $416M AUM

JP Morgan Chase

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vivo Capital's LBRX Position: Q1 2026 in Review

Vivo Capital held its LB Pharmaceuticals (LBRX) position steady in Q1 2026 at 800,000 shares worth $19.7M. The position accounts for 1.64% of the portfolio, ranked #21.

Vivo Capital first reported a position in LBRX in Q3 2025 and has held it in 3 quarters since. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

Vivo Capital held 800,000 shares of LB Pharmaceuticals worth $19.7M as of Q1 2026.
Vivo Capital left its LB Pharmaceuticals share count unchanged in Q1 2026.
LB Pharmaceuticals made up 1.64% of Vivo Capital's portfolio in Q1 2026, its #21 holding.
Vivo Capital first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.